ArticleAddiction (Abingdon, England)2025
GLP-1R agonist medications for addiction treatment.
Article in Addiction (Abingdon, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT06745128. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Tirzepatide for Individuals With Comorbid Obesity and Methamphetamine Use Disorder
Who cites it
16 citing papers in PubMed.
- Use of Glucagon-Like Peptide 1 Receptor Agonists and the Associated Risk of Hospitalisation in Bipolar Disorder, From a Nationwide Cohort, 2009-2024.Acta psychiatrica Scandinavica · 2026Article
- Polysubstance use disorders among US adults.Molecular psychiatry · 2026Article
- Innovations in health behavior research: Current status and strategic future directions.Experimental and clinical psychopharmacology · 2026Review
- Glucagon-like peptide 1 receptor agonists in substance use disorders: A systematic review of ClinicalTrials.Gov.Addictive behaviors reports · 2026Article
- Glucagon-like peptide-1 receptor agonists and risk of substance use disorders among US veterans with type 2 diabetes: cohort study.BMJ (Clinical research ed.) · 2026Article
- Characterizing app-based telemedicine for opioid use disorder treatment within the landscape of recovery-related smartphone applications.Addiction science & clinical practice · 2026Article
- Glucagon-like Peptide-1 receptor agonists as emerging therapeutics in bipolar disorder: a narrative review of preclinical and clinical evidence.Molecular psychiatry · 2026Review
- Lost in translation: why don't dopamine D2 antagonists cure addictions?Journal of psychiatry & neuroscience : JPN · 2026Article
- Crosstalk between alcohol use disorder and obesity: two sides of the same coin?Molecular psychiatry · 2025Review
- Review
- GLP-1 Therapeutics and Their Emerging Role in Alcohol and Substance Use Disorders: An Endocrinology Primer.Journal of the Endocrine Society · 2025Article
- Novel neurotherapeutic targets for substance use disorders: Neuroplasticity, neuroinflammation, gasotransmitters and non-canonical organ systems.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025Review
- Semaglutide: a key medication for managing cardiovascular-kidney-metabolic syndrome.Future cardiology · 2025Review
- Glucagon-like peptide-1 receptor agonists, but not dipeptidyl peptidase-4 inhibitors, reduce alcohol intake.The Journal of clinical investigation · 2025Article
- Effects of glucagon-like peptide-1 receptor agonists on psychiatric disorders: a systematic review.Therapeutic advances in psychopharmacology · 2025Review
- The Potential Utility of GLP-1 Receptor Agonist Medications for Addiction Treatment: A Narrative Review of Clinical and Epidemiological Evidence.Current addiction reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.